Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review

Huong Duong-Thi-Ly, Ha Nguyen-Thi-Thu, Long Nguyen-Hoang, Hanh Nguyen-Thi-Bich, Timothy J. Craig, Sy Duong-Quy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Numerous studies have examined the association between pharmacogenetic effects and the response to inhaled corticosteroids (ICS) in patients with asthma. In fact, several single nucleotide polymorphisms of a number of candidate genes have been identified that might influence the clinical response to ICS in children with asthma. Their direct or indirect effects depend on their role in the inflammatory process in asthma or the anti-inflammatory action of corticosteroids, respectively. Among the genes identified, variants in T-box 21 (TBX21) and Fc fragment of IgE receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 (CRHR1), nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 (STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS. The results to date indicate various potential genetic factors associated with the response to ICS, which could be utilized to predict the individual therapeutic response of children with asthma to ICS. Clinical trials are underway and their results are greatly anticipated. Further pharmacogenetic studies are needed to fully understand the effects of genetic variation on the response to ICS in children with asthma.

Original languageEnglish (US)
Pages (from-to)1818-1830
Number of pages13
JournalJournal of International Medical Research
Volume45
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Adrenal Cortex Hormones
Asthma
Genes
Anti-Inflammatory Agents
Vascular Endothelial Growth Factors
Histone Deacetylase 1
Dual Specificity Phosphatase 1
Corticotropin-Releasing Hormone Receptors
Immunoglobulin Fc Fragments
IgE Receptors
Sphingolipids
Pharmacogenetics
Phosphoproteins
Biosynthesis
Cytoplasmic and Nuclear Receptors
Polymorphism
Glucocorticoids
Single Nucleotide Polymorphism
Nucleotides
Association reactions

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Duong-Thi-Ly, Huong ; Nguyen-Thi-Thu, Ha ; Nguyen-Hoang, Long ; Nguyen-Thi-Bich, Hanh ; Craig, Timothy J. ; Duong-Quy, Sy. / Effects of genetic factors to inhaled corticosteroid response in children with asthma : a literature review. In: Journal of International Medical Research. 2017 ; Vol. 45, No. 6. pp. 1818-1830.
@article{7d77b461f2704719981c0edc793b09e1,
title = "Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review",
abstract = "Numerous studies have examined the association between pharmacogenetic effects and the response to inhaled corticosteroids (ICS) in patients with asthma. In fact, several single nucleotide polymorphisms of a number of candidate genes have been identified that might influence the clinical response to ICS in children with asthma. Their direct or indirect effects depend on their role in the inflammatory process in asthma or the anti-inflammatory action of corticosteroids, respectively. Among the genes identified, variants in T-box 21 (TBX21) and Fc fragment of IgE receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 (CRHR1), nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 (STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS. The results to date indicate various potential genetic factors associated with the response to ICS, which could be utilized to predict the individual therapeutic response of children with asthma to ICS. Clinical trials are underway and their results are greatly anticipated. Further pharmacogenetic studies are needed to fully understand the effects of genetic variation on the response to ICS in children with asthma.",
author = "Huong Duong-Thi-Ly and Ha Nguyen-Thi-Thu and Long Nguyen-Hoang and Hanh Nguyen-Thi-Bich and Craig, {Timothy J.} and Sy Duong-Quy",
year = "2017",
month = "12",
day = "1",
doi = "10.1177/0300060516683877",
language = "English (US)",
volume = "45",
pages = "1818--1830",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "6",

}

Effects of genetic factors to inhaled corticosteroid response in children with asthma : a literature review. / Duong-Thi-Ly, Huong; Nguyen-Thi-Thu, Ha; Nguyen-Hoang, Long; Nguyen-Thi-Bich, Hanh; Craig, Timothy J.; Duong-Quy, Sy.

In: Journal of International Medical Research, Vol. 45, No. 6, 01.12.2017, p. 1818-1830.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of genetic factors to inhaled corticosteroid response in children with asthma

T2 - a literature review

AU - Duong-Thi-Ly, Huong

AU - Nguyen-Thi-Thu, Ha

AU - Nguyen-Hoang, Long

AU - Nguyen-Thi-Bich, Hanh

AU - Craig, Timothy J.

AU - Duong-Quy, Sy

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Numerous studies have examined the association between pharmacogenetic effects and the response to inhaled corticosteroids (ICS) in patients with asthma. In fact, several single nucleotide polymorphisms of a number of candidate genes have been identified that might influence the clinical response to ICS in children with asthma. Their direct or indirect effects depend on their role in the inflammatory process in asthma or the anti-inflammatory action of corticosteroids, respectively. Among the genes identified, variants in T-box 21 (TBX21) and Fc fragment of IgE receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 (CRHR1), nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 (STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS. The results to date indicate various potential genetic factors associated with the response to ICS, which could be utilized to predict the individual therapeutic response of children with asthma to ICS. Clinical trials are underway and their results are greatly anticipated. Further pharmacogenetic studies are needed to fully understand the effects of genetic variation on the response to ICS in children with asthma.

AB - Numerous studies have examined the association between pharmacogenetic effects and the response to inhaled corticosteroids (ICS) in patients with asthma. In fact, several single nucleotide polymorphisms of a number of candidate genes have been identified that might influence the clinical response to ICS in children with asthma. Their direct or indirect effects depend on their role in the inflammatory process in asthma or the anti-inflammatory action of corticosteroids, respectively. Among the genes identified, variants in T-box 21 (TBX21) and Fc fragment of IgE receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 (CRHR1), nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 (STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS. The results to date indicate various potential genetic factors associated with the response to ICS, which could be utilized to predict the individual therapeutic response of children with asthma to ICS. Clinical trials are underway and their results are greatly anticipated. Further pharmacogenetic studies are needed to fully understand the effects of genetic variation on the response to ICS in children with asthma.

UR - http://www.scopus.com/inward/record.url?scp=85032195833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032195833&partnerID=8YFLogxK

U2 - 10.1177/0300060516683877

DO - 10.1177/0300060516683877

M3 - Article

C2 - 29251255

AN - SCOPUS:85032195833

VL - 45

SP - 1818

EP - 1830

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 6

ER -